fipr-16 Antibody

What is PI16 and what are its important molecular characteristics?

PI16 (Peptidase Inhibitor 16) is a protein encoded by the PI16 gene in humans. It may also be known by several alternative names including CRISP9, CD364, MSMBBP, PSPBP, PSP94-binding protein, and cysteine-rich secretory protein 9. From a structural perspective, the protein has a molecular weight of approximately 49.5 kilodaltons. Orthologs exist in several mammalian species including canine, porcine, monkey, mouse and rat, making it suitable for comparative studies .

What are the structural and functional properties of FGF-16?

FGF-16 (Fibroblast Growth Factor 16) is a growth factor protein that in recombinant form spans from Ala2 to Arg207 in the human protein sequence (Accession # O43320). Functionally, FGF-16 demonstrates significant mitogenic activity, specifically stimulating proliferation in fibroblast cell lines in a dose-dependent manner. Its activity can be experimentally neutralized using specific antibodies, with a typical Neutralization Dose (ND50) of 3-9 μg/mL when testing against 100 ng/mL of recombinant human FGF-16 .

What is the significance of IFI-16 in autoimmune conditions?

IFI-16 (Interferon-Inducible Protein 16) has demonstrated significant associations with autoimmune conditions, particularly scleroderma. Research has shown that anti-IFI-16 antibodies are significantly more prevalent in scleroderma patients compared to healthy controls (18% versus 2%, P = 0.01). These antibodies correlate with specific clinical manifestations including limited scleroderma subtype (77% versus 46% in antibody-negative patients), longer disease duration (median 15.2 years versus 6.0 years), digital gangrene (24% versus 4%), and reduced diffusing capacity for carbon monoxide (DLco) .

What are the optimal detection methods for PI16 in various experimental systems?

PI16 can be detected using multiple methodological approaches, with specific antibodies optimized for different applications. The table below summarizes common applications from various suppliers:

For optimal detection, researchers should select antibodies validated for their specific application and species of interest. Western blot appears to be the most universally supported application across suppliers, while specialized applications like flow cytometry may require specific conjugated antibodies .

How can researchers optimize immunohistochemistry protocols for FGF-16 detection in tissue samples?

FGF-16 detection in tissue samples requires careful optimization of antibody concentration, incubation conditions, and detection methods based on the specific tissue being analyzed. The following table presents validated protocols for different tissue types:

These protocols highlight the importance of tissue-specific optimization. For human heart tissue, a lower antibody concentration with overnight incubation provides optimal staining of cardiomyocytes, while embryonic tissues may require higher antibody concentrations to achieve sufficient signal .

What methods can be used to validate antibody specificity in FGF-16 functional studies?

Validation of antibody specificity in functional studies is essential for reliable research outcomes. For FGF-16 antibodies, a proliferation neutralization assay provides a robust validation method. This involves:

• Establishing a dose-response curve for cell proliferation using recombinant FGF-16 (typically in NR6R-3T3 mouse fibroblast cells)

• Demonstrating dose-dependent neutralization of this proliferative effect using the anti-FGF-16 antibody

• Calculating the Neutralization Dose (ND50), which for anti-FGF-16 antibodies typically falls between 3-9 μg/mL in the presence of 100 ng/mL recombinant human FGF-16

This functional validation confirms both the biological activity of FGF-16 and the neutralizing capacity of the antibody, providing greater confidence in experimental results .

How should researchers design experiments to investigate clinical associations of anti-IFI-16 antibodies?

When investigating clinical associations of anti-IFI-16 antibodies, a well-designed experimental approach is critical. Based on published research, an effective study design includes:

• Initial discovery cohort: Include both patients (e.g., scleroderma) and healthy controls to establish baseline prevalence and preliminary associations

• Targeted case-control study: Match cases and controls (1:1 ratio) based on disease duration to control for potential confounding variables

• Analytical methods: Employ multiple statistical approaches including:

  • Nonparametric matched pairs analysis

  • Univariate conditional logistic regression

  • Multivariable conditional logistic regression to control for potential confounders

This comprehensive approach allows researchers to establish not only the presence of associations but also their independence from potentially confounding clinical variables .

What considerations are important when implementing Design of Experiments (DOE) for antibody-related research?

Design of Experiments (DOE) offers a powerful approach for optimizing antibody-related research, particularly in areas like antibody-drug conjugate development. Key considerations include:

• Parameter selection: Identify critical process parameters that may affect antibody performance

• Statistical design selection: For early-phase research, factorial designs (full or fractional) are typically most appropriate

• Scale-down model selection: Ensure the scale-down model accurately represents the true process to avoid introducing undesired variability

• Factor ranges: Define appropriate ranges for critical parameters

The table below presents example factors and ranges used in antibody-drug conjugate development:

A full factorial design with center points (e.g., 16 experiments at corners with 3 center-points) provides robust data for model development while allowing identification of interaction effects between parameters .

How can researchers optimize the Drug Antibody Ratio (DAR) in antibody-based therapeutic development?

Optimizing Drug Antibody Ratio (DAR) is a critical aspect of antibody-based therapeutic development, particularly for antibody-drug conjugates. An effective approach involves:

• Defining target specifications: Establish acceptable ranges (e.g., DAR between 3.4-4.4) with an optimal target (e.g., 3.9)

• Implementing DOE: Design a factorial experiment investigating critical parameters affecting conjugation, including:

  • Protein concentration

  • Temperature

  • pH

  • Reduction time

• Creating a design space: Use experimental results to define a "sweet spot" or design space where all quality attributes meet specifications

• Calculating robust setpoints: Determine optimal process parameters that maximize the probability of achieving the target DAR while maintaining process robustness

This systematic approach creates a scientifically sound foundation for process development and facilitates eventual scale-up for clinical manufacturing .

What is the detailed association between anti-IFI-16 antibodies and clinical manifestations in scleroderma patients?

Anti-IFI-16 antibodies demonstrate significant associations with specific clinical features in scleroderma patients as outlined in the table below:

In a case-control study specifically examining digital gangrene, 45% (35/78) of scleroderma patients were anti-IFI-16 antibody positive. The strong association with digital gangrene suggests a potential pathogenic role in vascular manifestations of scleroderma, while the association with longer disease duration may indicate their development over time or their presence in patients with less aggressive disease course allowing longer survival .

How should researchers interpret contradictory antibody data in clinical studies?

When faced with contradictory antibody data in clinical studies, researchers should systematically:

• Evaluate methodological differences: Different detection methods (ELISA vs. immunoblot) may yield varying results

• Consider antibody specifications: Verify epitope specificity, as antibodies targeting different epitopes may yield different associations

• Analyze cohort characteristics: Differences in disease duration, severity, or treatment history may explain discrepancies

• Implement statistical controls: Use matched case-control designs and multivariable analysis to control for potential confounders

• Validate findings: Confirm key findings in independent cohorts

The contradictory findings often reflect the complex biology of autoantibodies, which may change over disease course or represent heterogeneous patient subgroups rather than simple methodological errors .

What strategies can researchers employ to optimize antibody specificity in Western blot applications?

When optimizing antibody specificity for Western blot applications of PI16, FGF-16, or IFI-16, researchers should consider the following strategies:

• Antibody selection: Choose antibodies validated specifically for Western blot applications

• Blocking optimization: Test different blocking agents (BSA, milk proteins, commercial blockers) to reduce background

• Antibody dilution: Titrate antibody concentrations to determine optimal signal-to-noise ratio

• Incubation conditions: Optimize both primary and secondary antibody incubation times and temperatures

• Washing protocol: Implement rigorous washing steps with appropriate detergent concentration

• Positive and negative controls: Include known positive samples and negative controls (ideally knockout or depleted samples)

• Validation with multiple antibodies: When possible, confirm findings using antibodies from different suppliers or targeting different epitopes

These optimization steps are essential for generating reliable and reproducible Western blot results, particularly when studying proteins like PI16 that may exist in multiple isoforms or have closely related family members .

How can researchers determine the optimal antibody concentration for immunohistochemistry applications?

Determining optimal antibody concentration for immunohistochemistry requires a systematic titration approach:

• Initial range finding: Test a wide concentration range (e.g., 1-20 μg/mL) on positive control tissues

• Narrow range optimization: Based on initial results, test a narrower range to fine-tune concentration

• Tissue-specific adjustment: Different tissues may require different concentrations (e.g., human heart tissue at 3 μg/mL versus mouse embryo at 15 μg/mL for FGF-16)

• Incubation optimization: Adjust incubation time and temperature in conjunction with concentration

• Signal amplification consideration: The detection system (direct fluorescence vs. enzymatic amplification) influences optimal primary antibody concentration

• Background evaluation: Assess non-specific staining at each concentration to identify the optimal signal-to-noise ratio

For FGF-16 antibodies specifically, published protocols indicate that concentrations between 3-15 μg/mL are typically effective, with lower concentrations sufficient for adult tissues and higher concentrations sometimes necessary for embryonic tissues .